Shanghai MicuRx Pharmaceutical Co., Ltd., a biopharmaceutical company, discovers, develops, and commercialize drugs for unmet medical needs. It is developing Contezolid (MRX-I) and Contezoilid acefosamil (MRX-4) oxazolidinone antibiotics for multidrug-resistant gram-positive bacteria; MRX-8 MRX, a polymyxin antibiotic, to target multidrug-resistant Gram-negative bacteria; MRX-5 for multidrug-resistant gram-negative bacteria; MRX-7 for multidrug-resistant gram-positive bacteria; MRX-15 and MRX-17 to treat kidney disease; MRX-18 for the treatment of COVID-19; and MRX-23 for the treatment of tumour. Shanghai MicuRx Pharmaceutical Co., Ltd. was founded in 2007 and is headquartered in Shanghai, China.
Metrics to compare | 688373 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship688373PeersSector | |
---|---|---|---|---|
P/E Ratio | −13.0x | −29.6x | −0.5x | |
PEG Ratio | −0.85 | 0.35 | 0.00 | |
Price/Book | 13.5x | 8.2x | 2.6x | |
Price / LTM Sales | 39.8x | 21.1x | 3.3x | |
Upside (Analyst Target) | −34.4% | 1.1% | 40.3% | |
Fair Value Upside | Unlock | −20.7% | 5.1% | Unlock |